Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Preclinical development of new nucleoside-based drug against leukemia

Project description

Taking a new leukaemia drug to the clinic

Hypomethylating agents are used in the treatment of leukaemia, particularly acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), to reverse abnormal DNA methylation patterns that contribute to disease progression. Despite their clinical utility, these agents often face instability issues and limited efficacy, especially in elderly or medically frail patients, highlighting the need for more stable and effective therapeutic options. The ERC-funded leuCAB project will support the preclinical development of carbacitabin (CAB), a novel compound that exhibits improved results and reduced toxicity. The study will undertake structure, safety and efficacy optimisation of CAB, scaling up its production for clinical trials.

Objective

The current treatment landscape for leukemia, particularly concerning AML (acute myeloid leukemia) and MDS (myelodysplastic syndrome), is constrained by the instability of hypomethylating agents which are regularly used in elderly, medically non-fit patients (high-risk). This instability restricts their spectrum of application, leaving a significant gap in effective treatment options. Despite research into alternative therapeutic approaches the need for a mild treatment option with high success rates in this patient population remains unmet.

Carbacitabin (CAB) emerges as a promising solution to these challenges. This novel epigenetically active compound exhibits enhanced stability against hydrolytic cleavage and enzymatic metabolization. In AML PDX mouse models, CAB demonstrates significantly improved efficacy and vastly reduced toxicity, making it an optimal candidate for leukemia treatment, particularly for those high-risk patients.

Funding from the ERC PoC aims to support essential preclinical steps towards fully realizing the potential of CAB. Those include, further optimization of the lead structure of CAB to enhance targeting and thorough preclinical studies to evaluate the safety and efficacy of CAB. Additionally, scaling up the synthesis of CAB is crucial to meet the demand for large-scale production required for preclinical and subsequent clinical trials. Furthermore, efforts to solidify intellectual property (IP) protection and conduct an in-depth freedom-to-operate (FTO) analysis are necessary to safeguard CAB's market position. Establishing a spin-off company dedicated to the clinical studies of CAB will require engagement with essential stakeholders, including potential investors, pharmaceutical partners, legal advisors, and regulatory consultants during leuCAB. This comprehensive approach will ensure the effective translation of CAB from bench to bedside, bringing new hope to patients, especially those battling AML and MDS.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Net EU contribution
€ 150 000,00
Address
GESCHWISTER SCHOLL PLATZ 1
80539 Planegg
Germany
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)